期刊文献+

度洛西汀与帕罗西汀治疗抑郁症的多中心双盲对照研究 被引量:12

Duloxetine versus paroxetine in the treatment of major depressive disorder:a randomized double-blind multicentre controlled study
原文传递
导出
摘要 目的:以帕罗西汀为对照,评价度洛西汀治疗抑郁症的疗效和安全性。方法:采用随机双盲多中心对照研究方法,244例患者纳入研究,度洛西汀组121例(60 mg.d-1),帕罗西汀组123例(20 mg.d-1),疗程8周。以汉密尔顿抑郁评定量表17项作为主要疗效评价指标。结果:度洛西汀组与帕罗西汀组的有效率分别为71.1%和71.5%(P>0.05)。度洛西汀的不良事件发生率(75.0%)高于帕罗西汀组(62.3%),差异有统计学意义(P=0.0381)。结论:度洛西汀治疗抑郁症的疗效与帕罗西汀相当,个别不良事件发生率度洛西汀高于帕罗西汀。 Objective: To evaluate the efficacy and safety of duloxetine in comparison with paroxetine in patients who met Diagnostic and Statistical Manual fourth edition(DSM-IV) criteria of major depressive disorder.Methods: A randomized,double-blind,controlled multicentre clinical trial was conducted.All subjects(n=244) were treated with either duloxetine 60 mg·d-1(n=121) or paroxetine 20 mg·d-1(n=123) for 8 weeks.The main efficacy measure was the change in total score of the Hamilton Depression Scale 17 item(HAMD17) from baseline to endpoint.Results: The response rates were 71.1%(duloxetine) and 71.5%(paroxetine).There were no significant differences between 2 groups.The efficacy of duloxetine was non-inferiority of paroxetine's in treatment of MDD.There were significantly higher adverse events in the duloxetine group(75.0%) than in the paroxetine group(62.3%,P=0.038 1).Conclusion: Duloxetine and paroxetine have similar therapeutic effect in treatment of patients with major depressive disorder,but duloxetine causes more adverse events.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第4期334-338,共5页 Chinese Journal of New Drugs
关键词 抑郁症 度洛西汀 帕罗西汀 疗效 安全性 major depressive disorder duloxetine paroxetine efficacy safety
  • 相关文献

参考文献14

  • 1BUDA M, TSUANG MT. The epidemiology of suicide: implications for clinical practice. In: S.I. Blumenthal and D.J. Kupfer, editors, suicide over the life cycle: risk factors, assessmerits and treatment of suicide patients[ M]. Washington DC : American Psychiatric Press, 1981.
  • 2BYMASTER FP, DRESHFIELD-AHMAD LJ, THRELKELD PC, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors [ J ]. Neuropsychopharmacology, 2001, 25 ( 6 ) : 871 - 880.
  • 3HUNZIKER ME, SUEHS BT, BETTINGER TL, et al. Duloxetine Hydrochloride: a new dual-acting medication for the treatment of major depressive disorder[ J]. Clin Ther, 2005, 27 (8) :1126 - 1143.
  • 4IYENGAR S, WEBSTER AA, HEMRICK-LUECKE SK, et al. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor, in persistent pain models in rats [J]. JPharmacolExp Ther, 2004, 311(2) :576 -584.
  • 5DETKE MJ, LU Y, GOLDSTEIN DJ, et al. Duloxetine 60mg once-daily for major depressive disorder: A randomized double- blind placebo controlled trial[ J ]. J Clin Psychiatry, 2002, 63 (4) :308 -315.
  • 6DETKE M J, LU Y, GOLDSTEIN D J, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression [ J ]. J Psyckiatr Res , 2002, 36 (6) : 383 - 390.
  • 7GOLDSTEIN D J, LU Y, DETKE MJ, et al. Ouloxetine in the treatment of major depressive disorder: A double-blind clinical trial[J]. J Clin Psychiatry, 2002, 63(3) :225 -231.
  • 8DUNNER DE, D'SOUZA DN, KAJDASZ DK, et al. Is treatment-associated hypomania rare with duloxetine : secondary analysis of controlled trials in non-bipolar depression [ J ]. J Affect Disord, 2005, 87(1):115 -119.
  • 9STEWART DE, WOHILREICH MM, MALLINCKRODT CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerabillty in male and female patients [J]. JAffect Disord, 2006, 94(1 -3) :183-189.
  • 10GREIST J, MCNAMARA RK, MALLINCKRODT CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine [ J ]. Clin Ther, 2004, 26(9) : 1446 - 1455.

同被引文献94

  • 1赵静,朱珠.度洛西汀临床应用的安全性[J].药物不良反应杂志,2005,7(4):304-306. 被引量:13
  • 2汤疏华 张明园.汉密尔顿抑郁量表、汉密尔顿焦虑量表、不良反应量表.上海精神医学杂志,1990,(2):38-39,42.
  • 3BRECHT S, DESAIAH D, MARECHAL ES, et al. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospital- ized for severe depression: a double-blind randomized trial[ J]. J Clin Psychiatry, 2011, 72(8) :1086 -1094.
  • 4GARTLEHNER G, THALER K, HANSEN RA, et al. The gen- eral and comparative efficacy and safety of duloxetine in major de- pressive disorder: a systematic review and meta-analysis [J]. Drug Saf, 2009, 32(12) :1159 -1173.
  • 5PERAHIA DG, MAINA G, THASE ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double- blind, placebo-controlled trial[J]. J Clin Psychiatry, 2009,70 (5) : 706 -716.
  • 6MANCINI M, GIANNI W, ROSSI A, et al. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data[ J]. Expert Opin Pharmacother, 2009, 10(5) : 847 -860.
  • 7Yoshimura R, Kishi T, Hori H, et al. Comparison of the efficacy between paroxetine and sertralineaugmented with aripiprazole in patients with refrac- tory major depressive disorder [J]. Prog Neuropsy- chopharmacol Biol Psychiatry, 2012, 39(2):355- 357.
  • 8Thase ME, Gelenberg A, Kornstein SG, et al. Comparing venlafaxine extended release and fluoxe- tine for preventing the recurrence of major depres- sion: Results from the PREVENT study[J]. J Clin Psychiatry, 2011, 45(3) :412-420.
  • 9Mandrioli R, Mercolini L, Saracino MA, et al. Se- lective serotonin reuptake inhibitors (SSRIs) : ther apeutic drug monitoring and pharmacological inter- actions[J]. Curr Med Chem, 2012, 19 (12) : 1846- 1863.
  • 10Coleman KA, Xavier VY, Palmer TL, et al. An in direct comparison of the efficacy and safety of des- venlafaxine and venlafaxine using placebo as the common comparator[J]. CNS Spectr, 2012, 17 (3) : 131-141.

引证文献12

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部